Further to the investor presentation I found this transcript of TELA Bio Q3 conference call where an analyst from Canaccord Genuity asked about the Next Science deal and the medium term prospects of it. The CEO of TELA Bio response is below.
Very favourable outlook on the Xperience product!
https://www.nasdaq.com/articles/tela-bio-inc.-tela-q3-2021-earnings-call-transcript
Ann: Investor Presentation, page-2
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.020(8.00%) |
Mkt cap ! $67.08M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 22.5¢ | $61.02K | 262.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 146848 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 3100 | 1 |
View Market Depth
| Last trade - 13.13pm 17/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |